Risk factor
Low default risk
Profitability factor
Very strong margins and returns
In Guru Portfolios
Manager | Fund | Portfolio Weight (%) | Change |
|---|---|---|---|
| Steven Cohen | Point72 Asset Management, L.P. | 0.2% | +0.11% |
| Kenneth Griffin | CITADEL ADVISORS LLC | 0.1% | -0.01% |
About
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.
Company Valuation
Based on key historical and expected multiples, the stock is slightly undervalued relative to its peers. In particular, the stock is underpriced on P/E, 'cheap' on EV/EBI
Target Price
The average target price of NOVO-B.CO is 317 and suggests 17.2% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to